



ClinicalTrials.gov identifier: NCT05118789

Have you or a loved one been newly diagnosed with ROS1-positive non-small cell lung cancer (NSCLC)?

Zidesamtinib (NVL-520) is an investigational therapy* that targets ROS1 and is specifically designed with the goal of addressing the combined medical needs of:

- Avoiding off-target side effects,
- Treating brain metastases, and
- Addressing mutations that can cause treatment resistance.

Talk to your doctor today to determine whether you or a loved one may be eligible to receive zidesamtinib through the ARROS-1 clinical trial. Participation in a clinical trial is voluntary, and there are FDA approved therapies available for the treatment of ROS1-positive NSCLC.

You may be eligible to join the TKI-naïve cohort if you:

- ✓ Age ≥ 18 years
- ✓ Have confirmed locally advanced or metastatic NSCLC
- ✓ Test positive for ROS1 rearrangement
- ✓ Have not been previously treated with a ROS1 TKI for NSCLC

For more information, visit www.clinicaltrials.gov (NCT05118789), or reach out to clinicaltrials@nuvalent.com.

Trial highlights

-  ARROS-1 is a global, multicenter, open-label study that includes a cohort open for enrollment of patients with advanced or metastatic ROS1-positive NSCLC, who have not been previously treated with a ROS1 TKI, at sites around the globe.
-  All patients enrolled in the trial will receive zidesamtinib. No participants will receive a placebo. Zidesamtinib is taken in pill form once a day.
-  Participants may be reimbursed for some non-medical costs related to study participation (e.g., hotel stays, travel, and meals). Your study doctor and staff can help you determine what costs are reimbursable.

* Investigational therapies have not been approved by FDA or any other regulatory agency

Frequently Asked Questions

What are ROS1 targeted therapies?

Tumor cells that are “ROS1-positive” carry changes in the ROS1 gene, identified through cancer genomic testing.

Certain genomic alterations like ROS1 rearrangements can drive tumor growth and survival. These are known as “driver alterations” and are critical targets for cancer therapy. Zidesamtinib is designed with the goal of inhibiting ROS1 even in the presence of mutations that enable resistance to other therapies.

If your cancer has tested positive for ROS1, talk to your doctor today to find out whether you or a loved one may be eligible to receive zidesamtinib through the ARROS-1 clinical trial.

EXPLORE

Is cancer genomic testing right for me?

Identifying your tumor’s specific driver alterations can help your doctor design a matched precision treatment plan for you.

If you have been diagnosed with NSCLC and are not sure if your tumor has been genomically tested or are not sure about your ROS1 status, ask your doctor today about testing options available to you.

What are clinical trials?

Clinical trials are research studies that test a new therapeutic intervention in people to determine if it is safe and effective.

Participation in clinical trials is voluntary, and participants may choose to leave a trial at any time. Individuals may be motivated to join a trial because:

- Treatments they have previously tried to address their health problem did not work.
- There is no treatment for their health problem.
- Trial participation makes them feel more actively involved in their health journey.
- They wish to contribute to health discoveries that may help others lead healthier lives.

Joining a clinical trial is a personal decision.

Talk to your doctor to learn more about potential benefits and risks of trial participation and determine if clinical trial participation is the right choice for you.